Somagen Returns to Operating Profit in H1... Eliminates Accumulated Deficit and Improves Financial Structure

Somagen (950200), a US-based multi-omics specialist analytics company, achieved a turnaround in performance in the first half of this year, returning to profitability in both operating profit and net profit. This was driven by the partial sale of a subsidiary’s stake, which boosted net profit, and the offsetting of the accumulated deficit in full, resulting in significant improvements to its financial structure.

On August 14, Somagen announced through its 2026 interim financial statements that it had recorded an operating profit of $93,000 (approximately KRW 140 million) in the first half of this year. The company had posted an operating loss of $530,000 during the same period last year, but managed to achieve an operating profit this year.

Revenue was $16.2 million (approximately KRW 24 billion), representing a slight decrease compared to the same period last year. However, the company explained that it managed to achieve an operating profit by focusing on cost reduction and improving its business structure.

The improvement in net profit was even more significant. Somagen’s net profit for the first half amounted to $1.41 million (about KRW 2.1 billion), representing a large-scale turnaround compared to the same period last year.

Net profit was significantly impacted by the partial sale of shares in its subsidiary, KEAN Health Corp. Somagen sold a portion of its stake in KEAN Health in the first half of this year, leading to KEAN Health being excluded from its consolidated subsidiaries.

As a result, related performance was reflected as a discontinued operations profit of approximately $1.47 million, driving the overall net profit increase. The turnaround in core operating profit, combined with the financial effects from investments and subsidiaries, led to an expanded net profit.

The company’s financial structure also changed significantly. In the first half of this year, Somagen utilized its capital surplus to offset its accumulated deficits as part of a financial restructuring effort.

Thus, the accumulated deficit, which had stood at $62.24 million at the end of last year, was completely eliminated. After the offset, the company secured retained earnings of $14.5 million (approximately KRW 2.24 billion), further improving its balance sheet and capital structure.

The company explained that these measures have allowed it to clear accumulated financial burdens from the past and establish a foundation for stable business operations. It also plans to continue its focus on cost reduction and organizational improvement in its core business to maintain profitability.

A Somagen representative stated, "The recent partial sale of KEAN Health shares and the offsetting of accumulated deficits were strategic decisions aimed at maximizing profitability and strengthening our financial structure. Having cleared past financial burdens and successfully turned a profit in the first half, we will continue to focus on reinforcing our core competitiveness in genome analysis in the US and maintain a stable, profitable trajectory."

Ultimately, Somagen not only returned to operating profitability through cost reduction in its core business, but also improved both its profitability and financial stability by selling its stake in KEAN Health and clearing accumulated deficits.

This content was produced with the assistance of AI translation services.